Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06010862 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

StatusRecruiting
PhasePhase 1
Started2023-09-30
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 8, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2023-11-06
Study Status v1
Re-verified, no change to tracked fields
2023-08-23
Original filing
Chongqing Precision Biotech Co., Ltd
36 trials monitored
See 1 trial at risk
Breast Cancer
5,180 trials monitored
See 256 trials at risk
Lung Cancer
4,033 trials monitored
See 210 trials at risk
Colorectal Cancer
2,904 trials monitored
See 127 trials at risk
and 4 more diseases
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
Trial Details
NCT Number NCT06010862
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Collaborators: The First Affiliated Hospital of Nanchang University
Conditions Gastric Cancer, Colon Cancer, Pancreas Cancer, Esophagus Cancer, Cholangiocarcinoma, Lung Cancer, Breast Cancer
Enrollment 36 participants
Start Date 2023-09-30
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2023-11-08